Objective:

To explore the efficacy and safety of ultrasound (US)-guided percutaneous microwave ablation (MWA) in patients with symptomatic adenomyosis.

Methods:

From July 2020 to June 2021

34 patients with symptomatic adenomyosis received US-

guided percutaneous MWA were included in this retrospective study. Uterus volume

adenomyosis volume

dysmenorrhea

menstrual blood volume

hemoglobin (Hb) level

symptom severity score (SSS) and health-related quality of life score (HRQL) were evaluated at 1-

3-

6- and 12-month of follow-up after treatment.

Results:

The median follow-up time was 12.00 (10.50

12.00) months. At the 12-month follow-up

median uterine volume decreased from the baseline volume of 148.45 (92.08

215.62) mL to 87.62 (55.90

132.97) mL (

P

＜0.001) and median adenomyosis volume decreased from 61.08 (31.28

93.38) mL to 13.33 (7.95

43.20) mL (

P

＜0.001). The visual analog scale (VAS)

Hb level

and pictorial blood loss assessment chart (PBAC) were significantly improved compared to the preoperative period (

P

＜0.05). Meanwhile

the postoperative SSS and the HRQL score also showedstatistically difference from those before MWA (

P

＜0.05). No major complications occurred and all minor complications were self-limiting.

Conclusion:

MWA is an effective and safe alternative for the symptomatic adenomyosis. Patients with adenomyosis treated with US-guided MWA resulted in a reduction in uterine volume and adenomyosis volume while significantly improving the symptoms of dysmenorrhea

anemia and menorrhagia.